Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells
eLife · 2023
DOI: 10.7554/elife.80254 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2023. Verfasst von Julieta Martino und 13 weiteren Autor:innen. Beteiligte Einrichtung: Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina. Hauptthemen laut MEDLINE: DNA Damage, Synthetic Lethal Mutations. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: L'Oréal, Agencia Nacional de Promoción Científica y Tecnológica, GlaxoSmithKline.
Abstract (Originalsprache)
The trapping of Poly-ADP-ribose polymerase (PARP) on DNA caused by PARP inhibitors (PARPi) triggers acute DNA replication stress and synthetic lethality (SL) in BRCA2-deficient cells. Hence, DNA damage is accepted as a prerequisite for SL in BRCA2-deficient cells. In contrast, here we show that inhibiting ROCK in BRCA2-deficient cells triggers SL independently from acute replication stress. Such SL is preceded by polyploidy and binucleation resulting from cytokinesis failure. Such initial mitosis abnormalities are followed by other M phase defects, including anaphase bridges and abnormal mitotic figures associated with multipolar spindles, supernumerary centrosomes and multinucleation. SL was also triggered by inhibiting Citron Rho-interacting kinase, another enzyme that, similarly to ROCK, regulates cytokinesis. Together, these observations demonstrate that cytokinesis failure triggers mitotic abnormalities and SL in BRCA2-deficient cells. Furthermore, the prevention of mitotic entry by depletion of Early mitotic inhibitor 1 (EMI1) augmented the survival of BRCA2-deficient cells treated with ROCK inhibitors, thus reinforcing the association between M phase and cell death in BRCA2-deficient cells. This novel SL differs from the one triggered by PARPi and uncovers mitosis as an Achilles heel of BRCA2-deficient cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
- Centro de Investigaciones en Bioquímica Clínica e Inmunología, CIBICI-CONICET, Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina.
- OncoPrecision, Córdoba, Argentina.
- Center for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, United States.
- GlaxoSmithKline-Trust in Science, Global Health R&D, Stevenage, United Kingdom.
- GlaxoSmithKline-Trust in Science, Global Health R&D, Upper Providence, United States.
ORCID-Profile: Sebastián Omar Siri, José Luis Bocco, Vanesa Gottifredi
Förderung
- L'Oréal
- Agencia Nacional de Promoción Científica y Tecnológica
- GlaxoSmithKline
- Consejo Nacional de Investigaciones Científicas y Técnicas
- Instituto Nacional del Cáncer
Zitieren
APA
Martino, J., Siri, S. O., Calzetta, N. L., Paviolo, N. S., Garro, C., Pansa, M. F., Carbajosa, S., Brown, A. C., Bocco, J. L., Gloger, I., Drewes, G., Madauss, K. P., Soria, G., & Gottifredi, V. (2023). Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells. eLife. https://doi.org/10.7554/elife.80254
Vancouver
Martino J, Siri SO, Calzetta NL, Paviolo NS, Garro C, Pansa MF, et al. Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells. eLife. 2023. doi:10.7554/elife.80254
BibTeX
@article{Martino2023,
author = {Martino, Julieta and Siri, Sebastián Omar and Calzetta, Nicolás Luis and Paviolo, Natalia Soledad and Garro, Cintia and Pansa, Maria F and Carbajosa, Sofía and Brown, Aaron C and Bocco, José Luis and Gloger, Israel and Drewes, Gerard and Madauss, Kevin P and Soria, Gastón and Gottifredi, Vanesa},
title = {Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells},
journal = {eLife},
year = {2023},
doi = {10.7554/elife.80254}
}
EUVIMED